KRAS Testing and Cetuximab Efficacy in Colorectal Cancer
Author Information
Author(s): Bando H, Yoshino T, Tsuchihara K, Ogasawara N, Fuse N, Kojima T, Tahara M, Kojima M, Kaneko K, Doi T, Ochiai A, Esumi H, Ohtsu A
Primary Institution: National Cancer Center Hospital East
Hypothesis
Does sensitive KRAS testing improve the prediction of cetuximab efficacy in colorectal cancer patients?
Conclusion
Sensitive and quality-controlled KRAS testing may provide improved predictive power to determine the efficacy of anti-epidermal growth factor antibodies.
Supporting Evidence
- The overall mutation rate was 37.0% by direct sequencing and 44.0% by ARMS/S.
- ARMS/S WT patients had a median progression-free survival of 5.0 months compared to 1.7 months for ARMS/S MUT patients.
- The response rate for ARMS/S WT patients treated with cetuximab was 16.0%.
Takeaway
This study found that a better test for KRAS mutations can help doctors know if a cancer treatment will work for patients with colorectal cancer.
Methodology
The study compared KRAS mutation detection using direct sequencing and ARMS/S in patients receiving cetuximab.
Potential Biases
The retrospective design may have led to selection bias.
Limitations
The study had a small sample size and was retrospective, which could introduce bias.
Participant Demographics
Patients were adults aged 20 and older with unresectable metastatic colorectal cancer.
Statistical Information
P-Value
0.001
Statistical Significance
p=0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website